NASDAQ:BLCM - Bellicum Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Bellicum Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.88 -0.26 (-12.15 %) (As of 01/24/2020 04:00 PM ET) Add Compare Today's Range$1.63Now: $1.88▼$2.2550-Day Range$0.80MA: $1.36▼$2.2952-Week Range$0.72Now: $1.88▼$4.14Volume3.11 million shsAverage Volume2.08 million shsMarket Capitalization$93.85 millionP/E RatioN/ADividend YieldN/ABeta1.64 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include Rivo-cel that is in Phase II/III clinical trials to improve hematopoietic stem cell transplantation outcomes in the treatment of hematologic malignancies, including leukemias, lymphomas, and inherited blood disorders; and BPX-601, an autologous GoCAR-T product candidate, which is in Phase I/II clinical trials for treating solid tumors expressing the prostate stem cell antigen. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BLCM Previous Symbol CUSIPN/A CIK1358403 Webhttp://www.bellicum.com/ Phone832-384-1100Debt Debt-to-Equity Ratio28.20 Current Ratio1.37 Quick Ratio1.37Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.12 million Price / Sales83.79 Cash FlowN/A Price / Cash FlowN/A Book Value$1.58 per share Price / Book1.19Profitability EPS (Most Recent Fiscal Year)($2.44) Net Income$-98,040,000.00 Net Margins-4,768.13% Return on Equity-280.67% Return on Assets-93.42%Miscellaneous Employees173 Outstanding Shares49,920,000Market Cap$93.85 million Next Earnings Date3/10/2020 (Estimated) OptionableOptionable Receive BLCM News and Ratings via Email Sign-up to receive the latest news and ratings for BLCM and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:BLCM Rates by TradingView Bellicum Pharmaceuticals (NASDAQ:BLCM) Frequently Asked Questions What is Bellicum Pharmaceuticals' stock symbol? Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM." How were Bellicum Pharmaceuticals' earnings last quarter? Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) posted its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, missing the consensus estimate of ($0.57) by $0.01. The biopharmaceutical company had revenue of $0.10 million for the quarter, compared to the consensus estimate of $0.30 million. Bellicum Pharmaceuticals had a negative return on equity of 280.67% and a negative net margin of 4,768.13%. View Bellicum Pharmaceuticals' Earnings History. When is Bellicum Pharmaceuticals' next earnings date? Bellicum Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Bellicum Pharmaceuticals. Has Bellicum Pharmaceuticals been receiving favorable news coverage? News coverage about BLCM stock has trended very negative this week, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Bellicum Pharmaceuticals earned a media sentiment score of -3.0 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Bellicum Pharmaceuticals. Who are some of Bellicum Pharmaceuticals' key competitors? Some companies that are related to Bellicum Pharmaceuticals include BioSpecifics Technologies (BSTC), Urovant Sciences (UROV), ProQR Therapeutics (PRQR), Progenics Pharmaceuticals (PGNX), DURECT (DRRX), Avedro (AVDR), AnaptysBio (ANAB), Xenon Pharmaceuticals (XENE), AMAG Pharmaceuticals (AMAG), Merus (MRUS), Lannett (LCI), Fulcrum Therapeutics (FULC), Avid Bioservices (CDMO), Kindred Biosciences (KIN) and OptiNose (OPTN). What other stocks do shareholders of Bellicum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bellicum Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Alliance Resource Partners (ARLP), AVEO Pharmaceuticals (AVEO), Cyberark Software (CYBR), TransEnterix (TRXC), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), FireEye (FEYE), ACADIA Pharmaceuticals (ACAD) and Editas Medicine (EDIT). Who are Bellicum Pharmaceuticals' key executives? Bellicum Pharmaceuticals' management team includes the folowing people: Mr. Richard A. Fair, Pres, CEO & Director (Age 50)Dr. Alan K. Smith, Exec. VP of Technical Operations (Age 61)Mr. Thomas J. Farrell, Consultant (Age 56)Mr. Atabak Mokari, Chief Financial Officer (Age 42)Ms. Rosemary Y. Williams, Interim Principal Accounting Officer, VP of Fin. & Controller When did Bellicum Pharmaceuticals IPO? (BLCM) raised $101 million in an initial public offering on Thursday, December 18th 2014. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray acted as the underwriters for the IPO and Trout Capital was co-manager. How do I buy shares of Bellicum Pharmaceuticals? Shares of BLCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Bellicum Pharmaceuticals' stock price today? One share of BLCM stock can currently be purchased for approximately $1.88. How big of a company is Bellicum Pharmaceuticals? Bellicum Pharmaceuticals has a market capitalization of $93.85 million and generates $1.12 million in revenue each year. The biopharmaceutical company earns $-98,040,000.00 in net income (profit) each year or ($2.44) on an earnings per share basis. Bellicum Pharmaceuticals employs 173 workers across the globe.View Additional Information About Bellicum Pharmaceuticals. What is Bellicum Pharmaceuticals' official website? The official website for Bellicum Pharmaceuticals is http://www.bellicum.com/. How can I contact Bellicum Pharmaceuticals? Bellicum Pharmaceuticals' mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The biopharmaceutical company can be reached via phone at 832-384-1100 or via email at [email protected] MarketBeat Community Rating for Bellicum Pharmaceuticals (NASDAQ BLCM)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 342 (Vote Outperform)Underperform Votes: 276 (Vote Underperform)Total Votes: 618MarketBeat's community ratings are surveys of what our community members think about Bellicum Pharmaceuticals and other stocks. Vote "Outperform" if you believe BLCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLCM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 1/25/2020 by MarketBeat.com StaffFeatured Article: Are analyst ratings accurate?
